一、董事局会议召开情况 深圳市海王生物工程股份有限公司（以下简称"公司"或"本公司"）第十届董 事局第四次会议通知于2025年12月19日发出，并于2025年12月22日以通讯会议的 形式召开。会议应参与表决董事9人，实际参与表决董事9人。会议的召开和表决 程序符合《公司法》和《公司章程》的规定。 二、董事局会议审议情况 证券代码：000078 证券简称：海王生物 公告编号：2025-069 深圳市海王生物工程股份有限公司 第十届董事局第四次会议决议公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 经与会董事审议，会议通过了如下议案： （一）审议通过了《关于控股子公司为资产转让事项提供担保的议案》 具体内容详见公司于本公告披露日在《证券时报》《证券日报》《中国证券 报》《上海证券报》及巨潮资讯网上刊登的《关于控股子公司为资产转让事项提 供担保的公告》。 表决结果：9 票同意，0 票反对，0 票弃权。 三、备查文件 1、经与会董事签字并加盖董事局印章的董事局决议； 2、其他文件。 特此公告。 深圳市海王生物工程股份有限公司 董 事 局 二〇二五年十二月二十二 ...

Group 1 - The three major indices showed mixed performance, with the Shanghai Composite Index up 0.16%, while the Shenzhen Component Index and the ChiNext Index fell by 1.29% and 2.17% respectively, with a total trading volume of approximately 1.66 trillion yuan [2] - The pharmaceutical retail sector saw a resurgence, with companies like Huaren Health and Shuyuan Pingmin rising by 20%, and Yixin Tang increasing by 10%, indicating strong market interest [2] - Ant Group announced an upgrade of its AI health application to "Ant Ai Fu," focusing on a "health+" strategy, which aims to assist users in managing their health like a personal friend [2] Group 2 - The commercial aerospace sector remains active, with Tianyin Electromechanical rising over 16% and Aerospace Huanyu increasing by 14.71%, reflecting investor confidence in the industry [3] - The Long March 12A reusable rocket, developed by China Aerospace Science and Technology Corporation, is set for its historic first launch in December 2025, marking a significant milestone in China's space endeavors [3] - A report from Huaxi Securities highlights a shift in the commercial aerospace sector towards reusable manufacturing, with companies like SpaceX leading the way in reducing costs through increased reuse and launch frequency [3] Group 3 - The Central Economic Work Conference emphasized expanding domestic demand as a top priority for 2025, focusing on structural changes in consumption to stimulate growth [4] - Bank stocks performed well, with Shanghai Bank, Chongqing Rural Commercial Bank, and Suzhou Bank showing positive movements, indicating investor confidence in the banking sector [4] Group 4 - CICC's report forecasts that listed banks will see revenue growth rates of 2.5% and 3.6% for 2026 and 2027 respectively, with net profit growth rates of 1.9% and 2.6% [5] - The battery, AI, and PCB sectors experienced collective declines, with companies like Huasheng Lithium Battery dropping over 10%, indicating potential challenges in these industries [5] - Other sectors such as brokerage, automotive, liquor, and semiconductors also faced downturns, with notable declines in stocks like Muxi and BYD [5]

New Stock Issuance - The new stock "健信超导" (code: 787805) is issued at a price of 18.58[1] - The new stock "昂瑞微" (code: 688790) is listed at a price of 83.06[1] Rights Issues and Offers - "荃银高科" (code: 300087) has a tender offer period from December 4, 2025, to January 5, 2026[1] - "天普股份" (code: 605255) has a tender offer period from November 20, 2025, to December 19, 2025[1] Delisting and Trading Alerts - "退市苏吴" (code: 600200) has 10 trading days remaining until the last trading day[1] - "ST广道" (code: 920680) has 12 trading days remaining until the last trading day[1] Stock Performance Alerts - "赛微电子" (code: 300456) has reported severe abnormal fluctuations[1] - "ST立方" (code: 300344) has also reported severe abnormal fluctuations[1]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医药商业板块主力资金净流出3.56亿元，游资资金净流出3613.06万元，散户资 金净流入3.92亿元。医药商业板块个股资金流向见下表： 证券之星消息，12月12日医药商业板块较上一交易日下跌0.97%，海王生物领跌。当日上证指数报收于 3889.35，上涨0.41%。深证成指报收于13258.33，上涨0.84%。医药商业板块个股涨跌见下表： ...

New Stock Issuance - Tian Su Measurement (证券代码: 301449) issued at a price of 36.80[1] - Xi Hua Technology (证券代码: 732248) issued at a price of 10.10[1] Tender Offer Periods - Tender offer for Quan Yin Gao Ke (证券代码: 300087) from December 4, 2025, to January 5, 2026[1] - Tender offer for Tian Pu Shares (证券代码: 605255) from November 20, 2025, to December 19, 2025[1] Trading Alerts - *ST Guang Dao (证券代码: 920680) has 13 trading days remaining until the last trading day[1] - *ST Su Wu (证券代码: 600200) has 11 trading days remaining until the last trading day[1] Abnormal Fluctuations - Sai Wei Electronics (证券代码: 300456) reported severe abnormal fluctuations[1] - Other stocks with abnormal fluctuations include *ST Li Fang (证券代码: 300344) and *ST Zheng Ping (证券代码: 603843)[1]

Group 1: New Stock Offerings - 荃银高科 (300087) has a tender offer period from December 4, 2025, to January 5, 2026[1] - 天普股份 (605255) has a tender offer period from November 20, 2025, to December 19, 2025[1] Group 2: Delisting and Trading Alerts - *ST广道 (920680) has 14 trading days remaining until the last trading day[1] - 退市苏吴 (600200) has 12 trading days remaining until the last trading day[1] Group 3: Stock Performance Alerts - 赛微电子 (300456) reported severe abnormal fluctuations[1] - 梦天家居 (603216) has an announcement dated December 3, 2025, regarding stock performance[1] Group 4: Other Notable Stocks - 海欣食品 (002702) has an announcement dated December 10, 2025[1] - 海王生物 (000078) has an announcement dated December 8, 2025[1]

Core Insights - The pharmaceutical and biotechnology index experienced a decline of 0.64% during the week, underperforming the Shanghai Composite Index by 1.34 percentage points, ending a two-week upward trend [4] - The National Healthcare Security Administration released the 2025 National Basic Medical Insurance Drug List, which included 114 products, achieving a success rate of 88% in negotiations, the highest in recent years [5] - The launch of the commercial health insurance innovative drug list included 19 drugs, complementing the basic medical insurance list and indicating a shift towards a multi-tiered healthcare system in China [5][19] Weekly Market Performance - The A-share market saw significant gains for Haiwang Bio, which rose by 71.20%, while Zhongsheng Pharmaceutical increased by 15.56% [2] - In the Hong Kong market, Jinxin Reproductive Medicine and Boan Biotechnology saw increases of 7.53% and 8.62%, respectively [2] Clinical Trials and Innovations - Kangfang Biopharma's dual-antibody drug, Kadunilumab, has initiated a Phase II clinical trial for esophageal squamous cell carcinoma, a prevalent cancer type in China [13][14] - A clinical trial for a gout treatment, polyethylene glycol-uricase injection (HZBio1), has also commenced, targeting patients with poorly controlled uric acid levels [17][18] New Drug Developments - Baoyi Pharmaceutical's stock surged nearly 140% on its first trading day, with a market capitalization of HKD 20.5 billion, despite a significant net loss of CNY 183 million in the first half of 2025 [6][7] - The company has 12 self-developed products, with SJ02 being the first long-acting FSH-CTP product approved in China [7] Industry Trends - The trend of "innovation + internationalization" remains a core direction for the pharmaceutical sector, supported by policies and increasing global competitiveness [5] - The demand for more effective and safer uric acid-lowering drugs is rising due to the increasing prevalence of gout, particularly among younger populations in China [18]

Group 1 - The flu epidemic in China is on the rise, leading to increased market speculation in related sectors such as retail pharmacies, vaccines, and flu medications [2][17] - The flu concept index has risen by 14.64% since the second half of the year, with 35 stocks in the sector showing gains, particularly Haiwang Biological, which saw its stock price double in a short period [2][17] - Haiwang Biological's stock price surge is disconnected from its financial performance, as the company has not disclosed the specific contribution of flu-related business to its earnings [3][18] Group 2 - Haiwang Biological's third-quarter report shows a revenue decline of 12.38% year-on-year, with a net profit drop of 44.39%, indicating a weakening core business [8][23] - The company's financials reveal a reliance on non-recurring gains for profit, raising concerns about sustainability [8][23] - The company has a high debt-to-asset ratio of 89.57% and significant accounts receivable, which poses liquidity risks [28][30] Group 3 - Haiwang Biological's core business is pharmaceutical distribution, which has low profit margins, while its manufacturing segment contributes minimally to overall revenue [10][25] - The company has faced continuous revenue declines and net losses over the past few years, accumulating losses of approximately 3.9 billion yuan [10][27] - The company attempted a restructuring plan with state-owned enterprises, which ultimately failed, highlighting ongoing operational challenges [30]

New Stock Listings - Baiaosaitu (688796) listed at an issue price of 26.68 on December 10, 2025[1] - Quanyin Gaoke (300087) has a tender offer period from December 4, 2025, to January 5, 2026[1] - Tiangong Co. (605255) has a tender offer period from November 20, 2025, to December 19, 2025[1] Delisting and Trading Alerts - ST Guangdao (920680) enters the delisting arrangement period starting December 11, 2025[1] - ST Suwu (600200) has 13 trading days remaining until the last trading day[1] Market Volatility - Hai Xin Food (002702) reported severe abnormal fluctuations[1] - Anji Food (603696) and other companies are under observation for abnormal trading activities[2] Additional Announcements - Multiple companies including Dongbai Group (600693) and Nanjing Business Travel (600250) have recent announcements linked to their stock codes[1] - Various companies are linked to announcements regarding abnormal fluctuations and trading activities[3]

Core Viewpoint - Haiwang Biological's stock experienced a 4.32% increase today, with a turnover rate of 20.79% and a trading volume of 2.498 billion yuan, indicating significant market activity and interest in the stock [2]. Trading Activity - The stock was listed on the daily trading board due to a price fluctuation of 19.38%, with a net selling amount of 27.31 million yuan from brokerage seats [2]. - The top five brokerage seats accounted for a total trading volume of 442 million yuan, with a buying amount of 207 million yuan and a selling amount of 235 million yuan, resulting in a net selling of 27.31 million yuan [2]. - The largest buying and selling brokerage was Guosen Securities Co., Ltd. Zhejiang Internet Branch, with buying and selling amounts of 56.36 million yuan and 62.41 million yuan, respectively [2]. Historical Performance - Over the past six months, the stock has appeared on the trading board seven times, with an average price increase of 3.59% the following day and an average increase of 18.92% over the next five days [3]. - The stock saw a net inflow of 34.82 million yuan from major funds today, with a significant inflow of 7.11 million yuan from large orders and 27.71 million yuan from major funds [3]. - In the last five days, the stock experienced a net outflow of 890 million yuan [3]. Margin Trading Data - As of December 9, the stock's margin trading balance was 180 million yuan, with a financing balance of 179 million yuan and a securities lending balance of 845,000 yuan [3]. - In the last five days, the financing balance decreased by 70.51 million yuan, representing a decline of 28.22%, while the securities lending balance increased by 159,400 yuan, reflecting a growth of 23.26% [3].